LOXL2 promotes the expression of stemness-related genes and EGFR in an IFIT1- and IFIT3-dependent manner, ultimately rendering oral squamous cell carcinoma more sensitive to the EGFR inhibitor gefitinib (Fig. 8k).906. This evidence concerns the gene LOXL2 and oral cavity squamous cell carcinoma.